Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Completed NCT07712536

Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitis

Conditions: Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD)

Sex: All

Ages: 12 Years – 18 Years

Healthy volunteers: No

Phase: PHASE2

Enrollment: 24

Sponsor: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Location: Hangzhou First People's Hospital Hangzhou Zhejiang

Summary

To evaluate the population pharmacokinetic characteristics of QY201 Tablets in adolescent participants with moderate to severe atopic dermatitis (AD).

Eligibility Criteria

Inclusion Criteria: 1. The participant and their parent/legal guardian (if applicable) shall have effective communication with the investigator, fully understand the purpose, nature, methods and potential adverse reactions of this trial, comprehend and comply with all requirements of the study, and sign the Informed Consent Form (ICF) prior to initiation of any study procedures. 2. Age ≥12 years and \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07712536). StuddyBuddy aggregates publicly available trial information.